Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2003-03-31
2008-11-18
Desai, Rita J (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S134000, C546S018000
Reexamination Certificate
active
07452905
ABSTRACT:
Specific phenylalanine derivatives or pharmaceutically acceptable salts thereof have an antagonistic effect on the α 4 integrins and, therefore, are usable as therapeutic agents or preventive agents for diseases in which α 4 integrin-depending adhesion process participates in the pathology, such as inflammatory diseases, rheumatoid arthritis, inflammatory bowel diseases, systemic lupus erythematosus, multiple sclerosis, Sjögren's syndrome, asthma, psoriasis, allergy, diabetes, cardiovascular diseases, arterial sclerosis, restenosis, tumor proliferation, tumor metastasis and transplantation rejection.
REFERENCES:
patent: 6197794 (2001-03-01), Head et al.
patent: 6388084 (2002-05-01), Kaplan et al.
patent: 6610710 (2003-08-01), Tanaka et al.
patent: 7160874 (2007-01-01), Tanaka et al.
patent: 7193108 (2007-03-01), Chiba et al.
patent: 2003/0220268 (2003-11-01), Makino et al.
patent: 2005/0222141 (2005-10-01), Sagi et al.
patent: 2006/0009476 (2006-01-01), Kataoka et al.
patent: 2006/0223836 (2006-10-01), Makino et al.
patent: WO 98/53814 (1998-12-01), None
patent: WO 99/10312 (1999-03-01), None
patent: WO 99/10313 (1999-03-01), None
patent: WO 99/30312 (1999-06-01), None
patent: WO 99/30313 (1999-06-01), None
patent: WO 99/35163 (1999-07-01), None
patent: WO 99/36393 (1999-07-01), None
patent: WO 99/37618 (1999-07-01), None
patent: WO 00/18759 (2000-04-01), None
patent: WO 01/12183 (2001-02-01), None
patent: WO 01/42215 (2001-06-01), None
patent: WO 02/02556 (2002-01-01), None
patent: WO 02/16329 (2002-02-01), None
Dorwald F. A. Side Reactions in Organic Synthesis, 2005, Wiley: VCH, Weinheim p. IX of Preface.
J. W. Tilley, et al.,Bioorganic&Medicinal Chemistry Letters, vol. 11, pp. 1-4 (2001).
Angela Zeidler et al, “Therapeutic Effects of Antibodies Against Adhesion Molecules in Murine Collagen Type II-Induced Arthritis”,Autoimmunity, 1995, vol. 21, pp. 245-252.
Daniel K. Podolsky et al, “Attenuation of Colitis in the Cotton-top Tamarin by Anti-α4 integrin Monoclonal Antibody”,J. Clin. Invest., Jul. 1993, vol. 92, pp. 372-380.
Tsutomu Takeuchi et al, “Upregulated Expression and Function of Integrin Adhesive Receptors in Systemic Lupus Erythematosus Patients with Vasculitis”,J. Clin. Invest., Dec. 1993, vol. 92, pp. 3008-3016.
S. M. Wellicome et al, “Detection of a circulating form of vascular cell adhesion molecule-1:raised levels in rheumatoid arthritis and systemic lupus erythematosus”,Clin. Exp. Immunol., 1993, vol. 92, pp. 412-418.
Ted A. Yednock et al, “Prevention of experimental autoimmune encephalomyelitis by antibodies against α4β1 integrin”,Nature, Mar. 5, 1992, vol. 356, pp. 63-65.
Jody L. Baron et al, “Surface Expression of β4 Integrin by CD4 T Cells Is Required for Their Entry into Brain Parenchyma”,J. Exp. Med., Jan. 1993, vol. 177, pp. 57-68.
Ichiro Saito et al, “Expression of Cell Adhesion Molecules in the Salivary and Lacrimal Glands of Sjogren's Syndrome”,Journal of Clinical Laboratory Analysis, 1993, vol. 7, pp. 180-187.
William M. Abraham et al, “β4-Integrins Mediate Antigen-induced Late Bronchial Responses and Prolonged Airway Hyperresponsiveness in Sheep”,J. Clin. Invest., Feb. 1994, vol. 93, pp. 776-787.
Hironori Sagara et al, “A Monoclonal Antibody against Very Late Activation Antigen-4 Inhibits Eosinophil Accumulation and Late Asthmatic Response in a Guinea Pig Model of Asthma”,Int. Arch. Allergy Immunol., 1997, vol. 112, pp. 287-294.
Sumi Onuma, “Immunohistochemical Studies of Infiltrating Cells in Early and Chronic Lesions of Psoriasis”,The Journal of Dermatology, 1994, vol. 21, pp. 223-232.
Toshinori Matsui et al, “Effects of anti-VLA-4 Monoclonal Antibody Treatment in Murine Model of Allergic Rhinitis”,Acta Otolaryngol., 2000, vol. 120, pp. 761-765.
Nobuyuki Ebihara et al, “Anti VLA-4 monoclonal antibody inhibits eosinophil infiltration in allergic conjunctivitis model of guinea pig”,Current Eye Research, 1999, vol. 19, No. 1, pp. 20-25.
Jody L. Baron et al, “The Pathogenesis of Adoptive Murine Autoimmune Diabetes Requires an Interaction between α4-Integrins and Vascular Cell Adhesion Molecule-1”,J. Clin. Invest., Apr. 1994, vol. 93, pp. 1700-1708.
Simcha R. Meisel et al, “Increased Expression of Neutrophil and Monocyte Adhesion Molecules LFA-1 and Mac-1 and Their Ligand ICAM-1 and VLA-4 Throughout the Acute Phase of Myocardial Infarction”,JACC, Jan. 1998, vol. 31, No. 1, pp. 120-125.
Peggy T. Shih et al, “Blocking Very Late Antigen-4 Integrin Decreases Leukocyte Entry and Fatty Streak Formation in Mice Fed and Atherogenic Diet”,Circ. Res., Feb. 19, 1999, vol. 84, pp. 345-351.
Alan B. Lumsden et al, “Anti-VLA-4 antibody reduces intimal hyperplasia in the endarterectomized carotid artery in nonhuman primates”,Journal of Vascular Surgery, Jul. 1997, vol. 26, No. 1, pp. 87-93.
Yoshihisa Mori et al, “Anti-α4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis”,Blood, Oct. 1, 2004, vol. 104, No. 7, pp. 2149-2154.
Hitoshi Okahara et al, “Involvement of Very Late Activation Antigen 4 (VLA-4) and Vascular Cell Adhesion Molecule 1 (VCAM-1) in Tumor Necrosis Factor α Enhancement of Experimental Metastasis”, Jun. 15, 1994, vol. 54, pp. 3233-3236.
Mitsuaki Isobe et al, “Immunosuppression to Cardiac Allografts and Soluble Antigens by Anti-Vascular Cellular Adhesion Molecule-1 and Anti-Very Late Antigen-4 Monoclonal Antibodies”,The Journal of Immunology, 1994, vol. 153, pp. 5810-5818.
Multiple Sclerosis: Meyers et al, J.Neuroimmunol, Antisense Drug Discovery, Mar. 2005; 160 (1-2): 12-24. Epub Dec. 23, 2004.
Asthma: Diamant et al,Clin Exp Allergy, “Effect of a very late antigen-4 receptor antagonist on allergen-induced airway responses and inflammation in asthma,” Aug. 2005; 35 (8): 1080-7.
Tumor metatasis: Garmy-Susini et al, “Integrin alpha4beta1-VCAM-1-mediated adhesion between endothelial and mural cells is required for blood vessel maturation,”J. Clin Invest., Jun. 2005; 115(6):1542-5. Epub May 2, 2005.
Transplantation rejection: Vu et al, “Sirolimus-mediated prolongation of rat cardiac allograft survival is enhanced by beta1 integrin very late antigen-4 blockade,”Transplant Proc., Jan.-Feb. 2005; 37(1):162-3.
U.S. Appl. No. 11/963,144, filed Dec. 21, 2007, Sagi, et al.
Murata Masahiro
Nakanishi Eiji
Suzuki Nobuyasu
Tsuji Takashi
Yoshimura Toshihiko
Ajinomoto Co. Inc.
Desai Rita J
Oblon & Spivak, McClelland, Maier & Neustadt P.C.
LandOfFree
Phenylalanine derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Phenylalanine derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phenylalanine derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4044660